Founders Fund VI Management
Latest statistics and disclosures from Founders Fund VI Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, CYTH, and represent 100.00% of Founders Fund VI Management's stock portfolio.
- Added to shares of these 1 stock: CYTH.
- Started 1 new stock position in CYTH.
- Reduced shares in these 1 stock: Applied Molecular Trans.
- Sold out of its position in Applied Molecular Trans.
- Founders Fund VI Management was a net buyer of stock by $45k.
- Founders Fund VI Management has $13M in assets under management (AUM), dropping by -3.47%.
- Central Index Key (CIK): 0001853382
Tip: Access up to 7 years of quarterly data
Positions held by Founders Fund VI Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Founders Fund VI Management
Founders Fund VI Management holds 2 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Roivant Sciences SHS (ROIV) | 98.6 | $13M | 1.1M | 11.23 |
|
|
Cyclo Therapeutics Com New (CYTH) | 1.4 | $175k | NEW | 110k | 1.59 |
|
Past Filings by Founders Fund VI Management
SEC 13F filings are viewable for Founders Fund VI Management going back to 2021
- Founders Fund VI Management 2023 Q4 filed Feb. 14, 2024
- Founders Fund VI Management 2023 Q3 filed Nov. 14, 2023
- Founders Fund VI Management 2023 Q2 filed Aug. 14, 2023
- Founders Fund VI Management 2023 Q1 filed May 15, 2023
- Founders Fund VI Management 2022 Q4 filed Feb. 14, 2023
- Founders Fund VI Management 2022 Q3 filed Nov. 14, 2022
- Founders Fund VI Management 2022 Q2 filed Aug. 15, 2022
- Founders Fund VI Management 2022 Q1 filed May 16, 2022
- Founders Fund VI Management 2021 Q4 filed Feb. 14, 2022